Takeda’s TYK2 inhibitor shows promising phase 2 results in psoriasis

A Takeda-manufactured inhibitor of TYK2 demonstrated a promising performance in a Phase 2 clinical trial for psoriasis, according to recently published data.

The inhibitor, TAK-779, was tested on a cohort of adult patients with moderate or severe plaque psoriasis, providing results that were both statistically significant and clinically meaningful. As 90% of patients showed improvement and the majority reached an “excellent” response, the drug proved to be a viable option for managing the condition.

The study, conducted on a double-blind, randomized, placebo-controlled basis, included over 200 patients in the United States and Europe. Participants were divided into groups, with some receiving varying doses of TAK-779 and others receiving a placebo. After 16 weeks, the results were evaluated.

The results showed that over 78% of patients receiving the highest dose of TAK-779 achieved a 75% improvement in their psoriasis area and severity index (PASI) score, the gold standard measure of psoriasis severity. This was significantly higher than the placebo group, in which only 10% achieved the same level of improvement.

In addition, the majority of patients in the treatment groups experienced few or no side effects. The most commonly reported adverse event was upper respiratory tract infection, which was reported in around 8% of patients receiving the highest dose of TAK-779.

Overall, the results of the Phase 2 trial demonstrate that TAK-779 is an efficacious treatment for psoriasis, with a favorable safety profile. Takeda is now planning to commence a Phase 3 clinical trial to further evaluate the drug’s efficacy and safety.

The findings of the Phase 2 trial provide a strong indication that TAK-779 may become a viable treatment option for psoriasis sufferers. With further evaluation, the drug may prove to be a beneficial addition to the range of options available for managing this condition.